Valeritas (NSDQ:VLRX) said today that its V-Go wearable insulin delivery system is available in Puerto Rico.
The Bridgewater, N.J.-based company has partnered with Fusion Consulting group to promote V-Go to Puerto Rico-based endocrinologists and general practitioners with Type II diabetes patients.
“We are excited to have partnered with Puerto Rico-based Fusion Consulting Group to help bring V-Go Wearable insulin delivery device to Puerto Rico,” Valeritas president & CEO John Timberlake said in prepared remarks.
“The prevalence of Type II diabetes is very high in Puerto Rico and we believe that the simple to use and very effective wearable delivery device can help a significant portion of patients with Type II diabetes currently using multiple-daily injections to deliver their insulin.”
According to the terms of the partnership, Valeritas will remain responsible for product development, regulatory approval, quality management and product manufacturing, while Fusion Consulting Group will be responsible for sales activity in Puerto Rico.
In November, Valeritas touted positive findings from an analysis of its V-Go system with a weekly physician-driven insulin titration algorithm.
Fifteen Type II diabetes patients in the study were evaluated after four months of using V-Go, the company said, and an A1C target of 7.5% or lower was achieved in 67% of patients. Hypoglycemia prevalence dropped from 23% at baseline to 7% of patients after four months.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.